Nanogen Pegcyte Clinical Study for the Prevention of CIN in Breast-cancer Patients.
Clinical trial NCT03381417 · COMPLETED
Trial details
- NCT number
- NCT03381417
- Sponsor
- Nanogen Pharmaceutical Biotechnology Joint Stock Company
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2016-10-06
- Primary completion
- 2017-11-06
- Enrollment
- 128
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.